Skip to main content
. 2017 Aug 9;6(2):213–223. doi: 10.1007/s40120-017-0081-9

Table 2.

pwINS baseline

Exposed (N = 24) Controls (N = 23) Total (N = 47) P
Illness duration (years)
 Mean ± SD 11.6 ± 12.3 19.7 ± 17.9 15.6 ± 15.6 0.080a
 Median [range] 6.2 [0.0, 39.3] 15.1 [1.1, 55.3] 9.9 [0, 55.3]
Familiarity for insomnia, N (%)c
 No 19 (79.2%) 13 (59.1%) 32 (69.6%) 0.139b
 Yes 5 (20.8%) 9 (40.9%) 14 (30.4%)
Sleep hygiene in use, N (%)
 No 8 (33.3%) 10 (43.5%) 18 (33.3%) 0.474b
 Yes 16 (66.7%) 13 (56.5%) 29 (61.7%)
Therapy pre-study, N (%)
 None 6 (25.0%) 2 (8.7%) 8 (17.0%)
 Melatonin ± anxiolytic 3 (12.5%) 4 (17.4%) 7 (14.9%)
 Benzodiazepines 9 (37.5%) 8 (34.8%) 17 (14.9%)
 Antidepressant ± analgesic 3 (12.5%) 4 (17.4%) 7 (14.9%)
 Antidepressant + benzodiazepine 3 (12.5%) 5 (21.7%) 8 (17.0%)

aWelch–Satterthwaite t test

bChi square test

c1 N/A among control